Open Access

Paclitaxel inhibits the migration of CD133+ U251 malignant glioma cells by reducing the expression of glycolytic enzymes

  • Authors:
    • Niya Long
    • Shuo Peng
    • Liangzhao Chu
    • Jun Jia
    • Minghao Dong
    • Jian Liu
  • View Affiliations

  • Published online on: September 9, 2020     https://doi.org/10.3892/etm.2020.9200
  • Article Number: 72
  • Copyright: © Long et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Energy metabolic reprogramming (EMR) allows for the rearrangement of a series of metabolic genes and proteins when tumor cells adapt to their microenvironment. EMR is characterized by changes in the metabolic pattern and metabolic intermediates to meet the needs of tumor cells for their malignant proliferation and infiltrative growth. The present study investigated the role of low‑dose paclitaxel (PTX) in changing the expression levels of key genes and proteins during glycolysis in CD133+ U251 glioma cells and explored the relevant regulatory mechanisms of action at the molecular level. CD133 immunomagnetic beads were applied to malignant CD133+ U251 glioma cells, which were then divided into a negative control and an experimental group treated with 1, 2, 4 or 8 µM PTX for 72 h. Cell Counting Kit‑8 (CCK‑8) was used to measure U251 cell proliferation. RNA and protein were extracted from the malignant glioma cells in all groups to observe changes in the expression levels of key glycolytic enzymes, such as glucose transporter 1 (GLUT1), pyruvate kinase M (PKM) and lactate dehydrogenase A (LDHA), using reverse transcription‑quantitative PCR and western blot assays. Transwell migration assays were performed to quantify the effects of PTX solution on U251 cells. CD133+ U251 glioma cells were isolated successfully. CD1133+ cells had a higher rate of proliferation compared with CD1133 cells. In CD1133+ cells treated with PTX, a dose‑dependent reduction in the expression levels of the key glycolytic enzymes GLUT1, PKM and LDHA was observed at both the mRNA and protein levels. PTX solution also inhibited cell migration. Differences between the control and experimental groups were statistically significant (P<0.05). Since glycolysis plays an indispensable role in the proliferation and migration of stem cell‑like glioma cells, PTX may inhibit tumor cell growth by downregulating the gene and protein expression levels of glycolytic enzymes in CD133+ glioma cells.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Long N, Peng S, Chu L, Jia J, Dong M and Liu J: Paclitaxel inhibits the migration of CD133<sup>+</sup> U251 malignant glioma cells by reducing the expression of glycolytic enzymes. Exp Ther Med 20: 72, 2020
APA
Long, N., Peng, S., Chu, L., Jia, J., Dong, M., & Liu, J. (2020). Paclitaxel inhibits the migration of CD133<sup>+</sup> U251 malignant glioma cells by reducing the expression of glycolytic enzymes. Experimental and Therapeutic Medicine, 20, 72. https://doi.org/10.3892/etm.2020.9200
MLA
Long, N., Peng, S., Chu, L., Jia, J., Dong, M., Liu, J."Paclitaxel inhibits the migration of CD133<sup>+</sup> U251 malignant glioma cells by reducing the expression of glycolytic enzymes". Experimental and Therapeutic Medicine 20.5 (2020): 72.
Chicago
Long, N., Peng, S., Chu, L., Jia, J., Dong, M., Liu, J."Paclitaxel inhibits the migration of CD133<sup>+</sup> U251 malignant glioma cells by reducing the expression of glycolytic enzymes". Experimental and Therapeutic Medicine 20, no. 5 (2020): 72. https://doi.org/10.3892/etm.2020.9200